Thibault Leray is a PhD student in the Department of Cellular Therapy at Oslo University Hospital. He completed his undergraduate and master’s degrees at Ecole Normale Superieure Paris-Saclay and University of Paris, graduating with a master in Immunology and Immunopathology.
His master’s thesis focused on human innate lymphoid cells’ metabolism modifications and plasticity under different cytokines exposure. Interested in immunotherapy development, he joined the Tang Lab at University of California, San Francisco as a visiting graduate student. There, he worked on TCR-engineered Tregs targeting pancreatic islets antigens to treat and revert type 1 diabetes.
In the MELOMANES project, Thibault will work on the development of universal CAR and T cell receptor-based combination therapy for melanoma treatment.
